Technical Note

Cryopreserved, Viable Osteochondral Allograft for the Treatment of a Full-Thickness Cartilage Defect of the Glenoid

Raffy Mirzayan, M.D., Benjamin Sherman, D.O., and Jorge Chahla, M.D., Ph.D.

Abstract: Glenoid chondral injuries constitute challenging injuries to treat because of the limited access and the limited options and evidence available for their resolution. The purpose of this Technical Note is to describe the procedure, pearls, and pitfalls of implantation of a cryopreserved osteochondral allograft (Cartiform) for the treatment of full-thickness cartilage defects of the shoulder. Cartiform is a cryopreserved osteochondral allograft composed of chondrocytes, chondrogenic growth factors, and extracellular matrix proteins that can be implanted through a single-stage procedure.

Chondral and osteochondral lesions in the shoulder can cause significant pain and can be challenging to treat. Lesions of the glenoid are the most difficult to manage and typically occur in young patients as a result of an acute traumatic shoulder dislocation or chronic shoulder instability that results in delamination of the articular cartilage. There is no established treatment in the literature; however, a trial of conservative treatment with physical therapy, anti-inflammatory medications, and corticosteroid injections is often performed. If conservative treatment fails, there are a number of available surgical techniques to address the pathology. However, limited clinical evidence exists to support the superiority of 1 technique. The treatments are often extrapolated from clinical evidence in similar defects present in the knee.

Available surgical techniques for glenoid cartilage defects include debridement, microfracture, autologous chondrocyte implantation, osteochondral allograft, interpositional arthroplasty with dermal allograft, or arthroplasty. Osteochondral allografts contain viable chondrocytes, chondrogenic growth factors, and extracellular matrix proteins to promote cartilage repair. They are available in fresh, fresh-frozen, or cryopreserved forms. Fresh osteochondral allografts have the highest percentage of viable chondrocytes but suffer from a shelf life of approximately 30 days and require precise preoperative sizing, whereas fresh-frozen allografts have minimal viable chondrocytes. Cryopreserved osteochondral grafts were reported to have up to a 2-year shelf life and may maintain up to 70.5% of viable chondrocytes. The advantages and disadvantages of cryopreserved osteochondral allografts are outlined in Table 1. The purpose of this Technical Note is to describe the surgical procedure, pearls, and pitfalls of implantation of a cryopreserved osteochondral allograft for the treatment of full-thickness cartilage defects of the shoulder.

Surgical Technique

Indications

Indications include large focal osteochondral lesions or lesions not amenable to microfracture at the glenoid surface.

Preoperative Preparation and Positioning

The patient is positioned in the lateral decubitus position under general anesthesia. Prophylactic antibiotics are given intravenously, and the operative arm is
prepared in the standard sterile fashion and draped free (Video 1).

**Portal and Cannula Placement**

The inflow cannula is inserted into the standard posterior portal, followed by the creation of a high anterior portal, anterior to the supraspinatus, using an outside-in technique. The portal incision should be large enough to allow placement of an 8-mm Gemini cannula (Arthrex, Naples, FL), which has inner and outer sheaths. The outer sheath has a dam to prevent fluid escape, but once the inner sheath is removed, the outer sheath can remain in place to allow for unresisted graft passage. A diagnostic arthroscopy is then performed. A second, percutaneous, 5.4-mm metal cannula is inserted through a trans-subscapularis (5-o’clock) portal.

**Graft Site Preparation**

A combination of shaver and curettes is used to debride and remove the pathologic cartilage and the calcified cartilage layer throughout the base of the defect, leaving healthy subchondral bone exposed.

Next, curettes are used to develop sharp borders of normal cartilage around the defect. Creation of a stable border with normal cartilage and a healthy layer of subchondral bone is the key to successful integration. A calibrated probe or arthroscopic ruler is used to measure the defect to accurately size the graft (Figs 1 and 2). Microfracture of the defect may be performed per surgeon discretion.

**Graft Preparation**

The osteochondral allograft consists of full-thickness articular cartilage and a thin layer of subchondral bone. In the case of Cartiform (Osiris, Columbia, MD), the graft comes with perforations in the articular cartilage, which allow for flexible conformity and improved integration to the underlying subchondral bone. The graft comes in a sterile jar, which should be placed into a sterile basin. Saline solution is added until the liquid level rests just below the lid. The jar is left in place for approximately 10 minutes or until there are no visible ice crystals. Once thawed, the graft may be removed from the jar with forceps and placed into a basin of sterile saline solution at room temperature. The graft should remain in the saline solution for at least 1 minute but may remain for up to 2 hours (Fig 3).

**Graft Implantation**

The allograft is sized and cut using a scalpel or scissors to match the desired shape and size. A metal drill sleeve is inserted through the anterosuperior (Gemini) cannula, and a 2.4-mm drill is used to drill a hole for the anchor at the 12-o’clock position of the lesion. A 3-mm BioComposite Knotless SutureTak (Arthrex) is then inserted. Another anchor is placed at the 3-o’clock position through the trans-subscapularis metal cannula. A third anchor is placed at the 6-o’clock position of the

---

**Table 1. Advantages and Disadvantages of Cryopreserved Osteochondral Allograft Implantation**

| Advantages                        | Disadvantages                        |
|-----------------------------------|--------------------------------------|
| No donor-site morbidity           | Treatable defect limited to 20-mm × 25-mm defect |
| Single operation                  | Allograft disease transmission is theoretically possible |
| Long shelf life                   | Technically demanding                |
| Implant flexibility, easily contoured |                                      |
| Minimal bone and low risk of reaction |                                    |

---

Fig 1. (A) Glenoid chondral defect as viewed from the posterior portal in a right shoulder with the patient in the lateral decubitus position. (B) An arthroscopic ruler can be used to measure the chondral defect.
lesion through the same cannula. The fourth and final anchor is placed at the 9-o’clock position of the lesion from the anterosuperior cannula. Each anchor has 3 suture strands that are then meticulously retrieved, brought out of the anterosuperior (Gemini) cannula, and kept separated (Fig 4).

A measuring tool is used to confirm the distance between the anchors to ensure the graft has been sized correctly. A needle is then used to pass the FiberWire suture (Arthrex) end (white) from the 12-o’clock anchor through the perforations of the graft with the corresponding 12-o’clock position. The free end of the FiberWire suture is placed through the loop of a 2-mm FiberLink (Arthrex) to shuttle the FiberWire into the locking mechanism of the anchor. We strongly recommend passing the sutures through the second perforation of the graft to prevent suture cutting through the graft. The same step is repeated with the other 3 anchors with their corresponding positions to the graft. The inflow is then turned off, and the graft is covered with a thin layer of fibrin glue using a dry arthroscopic technique (Fig 5). The surgical pearls and pitfalls are summarized in Table 2.

**Postoperative Management**

The patient is placed in a padded shoulder sling for comfort for 2 to 3 weeks. The patient is encouraged to perform immediate pendulum and passive range-of-motion exercises. No active range of motion or lifting is allowed for the first 6 weeks. After 6 weeks, active range of motion is initiated along with a strengthening program. Throwing is not permitted until 6 months after surgery if symptoms have resolved, with a return to sport at 10 to 12 months.
Chondral and osteochondral defects of the gleno-humeral joint can cause significant pain and disability. A variety of surgical techniques are available without the demonstrated superiority of 1 technique. Small lesions may respond well to microfracture and medium-sized lesions may respond well to autologous chondrocyte implantation, whereas large defects with an osseous component are often best treated with osteochondral allografts to prevent significant donor-site morbidity and multiple procedures. Cryopreserved osteochondral allografts (Cartiform) maintain a high percentage of viable chondrocytes and contain chondrogenic factors and extracellular matrices, which provide a sound scaffolding for cartilage repair without sacrificing shelf life. There are limited studies on osteochondral allograft use in shoulders, and these are composed mainly of case reports and case series.

A recent study by Riff et al. evaluated 20 patients (average age, 24.8 years) who had undergone osteochondral allograft transplantation for glenohumeral defects. At a mean of 67 months, 90% of grafts had incorporated, 20% of patients had undergone subsequent arthroplasty, and 55% of patients were satisfied. Similar results were seen in 13 patients with humeral head defects treated with an osteochondral allograft in a case series by Diklic et al. At a mean of 54 months, 69% of patients were pain free with no activity restrictions. These studies indicate that osteochondral allografts may be beneficial for glenohumeral joint treatment. At this time, there are no studies using cryopreserved osteochondral allograft in the shoulder; however, good short-term clinical results have been seen in the knee and ankle in case series.

This article describes a surgical technique for implantation of a cryopreserved osteochondral allograft (Cartiform) for the treatment of full-thickness cartilage defects of the shoulder. The risks and limitations of this technique are minimal. There is a potential risk of disease transmission from an allograft. The graft is soft and malleable; thus, sutures can potentially pull through the graft if pulled under tension. We recommend placing the sutures in the second hole from the periphery of the graft to minimize suture cutting through. The graft is obtained from the knee of a donor; therefore, the cartilage will be thicker than the native glenoid articular cartilage. This did not appear to be clinically significant. Further clinical research is needed to elucidate the outcomes and optimal fixation of cryopreserved osteochondral allografts in the shoulder.

### Table 2. Surgical Pearls and Pitfalls

| Pearls | Pitfalls |
|--------|----------|
| The surgeon should perform diagnostic arthroscopy before opening the graft to ensure the patient is a candidate. | The graft should be oriented to prevent placing the wrong side down. |
| The inner (clear) sheath from the anterosuperior (Gemini) cannula is removed, leaving the blue outer sheath of the cannula in the joint. The outer sheath does not have a dam within it, thus allowing easy passage of the graft and sutures without resistance. Once the graft is inserted into the joint, the suture limb that tightens the knotless anchors is sequentially pulled from each anchor until all the slack is removed from each anchor. | Placement of microfracture holes too closely should be avoided. |
| If a suture cuts through the graft, a suture-shuttling device can be used to pass the suture limbs through the graft and reanchor it with a PushLock anchor (Arthrex). The surgeon should use a probe to remove suture slack to avoid cutout from the graft. Microfracture of the defect may be performed based on surgeon discretion. | Insufficient debridement and preparation of the cartilage borders and bony bed should be avoided. |
References

1. Edmonds EW, Heyworth BE. Osteochondritis dissecans of the shoulder and hip. Clin Sports Med 2014;33:285-294.
2. McCarty LP III, Cole BJ. Nonarthroplasty treatment of glenohumeral cartilage lesions. Arthroscopy 2005;21:1131-1142.
3. Seidl AJ, Kraeutler MJ. Management of articular cartilage defects in the glenohumeral joint. J Am Acad Orthop Surg 2018;26:e230-e237.
4. Saltzman BM, Leroux T, Cole BJ. Management and surgical options for articular defects in the shoulder. Clin Sports Med 2017;36:549-572.
5. Becerra J, Andrades JA, Guerado E, Zamora-Navas P, Lopez-Puertas JM, Reddi AH. Articular cartilage: Structure and regeneration. Tissue Eng Part B Rev 2010;16:617-627.
6. Geraghty S, Kuang JQ, Yoo D, LeRoux-Williams M, Vangsness CT Jr, Danilkovitch A. A novel, cryopreserved, viable osteochondral allograft designed to augment marrow stimulation for articular cartilage repair. J Orthop Surg Res 2015;10:66.
7. Riff AJ, Yanke AB, Shin JJ, Romeo AA, Cole BJ. Midterm results of osteochondral allograft transplantation to the humeral head. J Shoulder Elbow Surg 2017;26:e207-e215.
8. Diklic ID, Ganic ZD, Blagojevic ZD, Nho SJ, Romeo AA. Treatment of locked chronic posterior dislocation of the shoulder by reconstruction of the defect in the humeral head with an allograft. J Bone Joint Surg Br 2010;92:71-76.
9. Vangsness CT Jr, Higgs G, Hoffman JK, et al. Implantation of a novel cryopreserved viable osteochondral allograft for articular cartilage repair in the knee. J Knee Surg 2018;31:528-535.
10. Rodriguez EG, Hall JP, Smith RL, Rachoy JP, Szmyd T. Treatment of osteochondral lesions of the talus with cryopreserved talar allograft and ankle distraction with external fixation. Surg Technol Int 2006;15:282-288.